ASN-002
AXP000149.1 · Viral vector gene therapy
- Platform
- adenovirus (non-replicating, IFN-gamma)
- Targets
- IFNG
- Originator
- Transgene
- Sponsor
- Ascend Biopharmaceuticals
Names
| Name | Type | Source |
|---|---|---|
| ASN-002 | preferred name, code | curator, ncit |
| Ad-IFNg ambiguous | synonym | ncit |
| TG1042 | former code | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Adenoviridae
- Virus
- human adenovirus
- Replication
- non replicating
- Modifications
- non-replicating adenoviral vector encoding human interferon gamma
- Transgenes
- IFNG
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C66972
Approvals
No regulatory approval recorded.
Clinical trials (10)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04416516 | Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor | Completed | Phase 2 | 2020-07-16 | 2024-02-14 | 21 | Basal Cell Carcinoma; Basal Cell Nevus Syndrome |
| NCT03728504 | Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema | Completed | Phase 2 | 2019-01-03 | 2020-04-29 | 97 | Chronic Hand Dermatitis |
| NCT03641573 | Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects | Completed | Phase 1 | 2018-10-11 | 2018-10-21 | 8 | Healthy Volunteer |
| NCT03654755 | Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis | Terminated | Phase 2 | 2018-09-29 | 2019-10-29 | 162 | Atopic Dermatitis |
| NCT03531957 | Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) | Completed | Phase 2 | 2018-07-05 | 2019-07-22 | 244 | Atopic Dermatitis |
| NCT03208296 | Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS) | Suspended | Phase 1/2 | 2017-12-01 | 2024-12-31 | 24 | Basal Cell Carcinoma in Basal Cell Nevus Syndrome |
| NCT03139981 | A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis | Completed | Phase 1 | 2017-04-12 | 2017-11-05 | 36 | Dermatitis Eczema; Dermatitis, Atopic; Dermatitis, Eczematous |
| NCT02853643 | Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers | Completed | Phase 1 | 2016-07 | 2016-11 | 22 | Healthy Volunteers |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma | Completed | Phase 1/2 | 2015-09 | 2017-11 | 16 | Basal Cell Nevus Syndrome; Nodular Basal Cell Carcinoma of Skin; Skin Neoplasm |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | Terminated | Phase 1/2 | 2015-05 | 2018-06 | 51 | B-Cell Chronic Lymphocytic Leukemia; B-Cell Leukemia, Chronic; B-Lymphocytic Leukemia, Chronic; Cancer; Chronic Idiopathic Myelofibrosis; Chronic Lymphocytic Leukemia; Idiopathic Myelofibrosis; Leukemia, Lymphocytic, Chronic; Leukemia, Lymphocytic, Chronic, B Cell; Lymphoma, B-cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Malignant; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T Cell, Peripheral; Myelofibrosis; Neoplasm; Peripheral T-Cell Lymphoma; T-Cell Lymphoma, Peripheral; Tumor |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT01082887 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | Terminated | Phase 1/2 | 2010-01 | 2012-10 | 18 | Metastatic Melanoma | name in title: Ad-IFNg |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39760239 | Skin Tape Stripping Reveals Distinct Biomarker Profiles in Chronic Hand Eczema of Patients With and Without Comorbid Atopic Dermatitis. | Allergy | 2025 | cited by trial NCT03728504 |
| PMID 25846669 | Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. | Cancer immunology, immunotherapy : CII | 2015 | name in title: TG1042 |
| PMID 24586226 | TG1042 (Adenovirus-interferon-γ) in primary cutaneous B-cell lymphomas: a phase II clinical trial. | PloS one | 2014 | name in title: TG1042 |
| PMID 24063735 | Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. | Journal of translational medicine | 2013 | name in title: TG1042 |
| PMID 20372104 | Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in title: TG1042 |
| PMID 15161670 | Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. | Blood | 2004 | name in abstract: TG1042 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 17621880 | Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. | Current opinion in investigational drugs (London, England : 2000) | 2007 | name in title: TG1042 |
| PMID 15333750 | Gene-based vaccines and immunotherapeutics. | Proceedings of the National Academy of Sciences of the United States of America | 2004 | name in abstract: TG1042 |
Notes
Adenovirus encoding human interferon gamma, injected into skin tumours. Developed by Transgene as TG1042 for cutaneous T-cell lymphoma, later taken forward by Ascend Biopharmaceuticals as ASN-002 for basal cell carcinoma (phase 2). Adenovirus serotype not verified.
How to cite
ASN-002 (AXP000149.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000149.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.